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ABSTRACT

ARTICLE HISTORY

One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently
licensed in the USA (M-M-R II; Merck, USA) and another has been developed (PriorixTM [MMR-RIT, GSK,
Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R
II or MMR-RIT at 12–15 months of age in the primary study (NCT00861744), were followed-up for 2 y postvaccination. Anti-measles and anti-rubella antibodies were measured using Enzyme-Linked
Immunosorbent Assay (ELISA), and anti-mumps antibodies using ELISA and plaque reduction
neutralization (PRN) assays. Serious adverse events (SAEs) were recorded during the entire follow-up. The
according-to-protocol (ATP) persistence cohort included 752 children (M-M-R II D 186, MMR-RIT D 566),
who received primary vaccination at a mean age of 12.3 ( § 0.67) months. 104 children were revaccinated
with MMR-containing vaccines; therefore, serology results for timepoints after revaccination were
excluded from the analysis. Seropositivity for measles (Year 1 98.3%; Year 2 99.4%) and rubella (Year
1 98.9%; Year 2 D 100%) remained as high at Year 2 as at Day 42. Similarly, seropositivity for mumps
determined by ELISA (Year 1 90.1%; Year 2 94.1%) and PRN assays (Year 1 87.5%; Year 2 91.7%)
persisted. Thirty-three SAEs were recorded in 23 children; 2 SAEs (inguinal adenitis and idiopathic
thrombocytopenic purpura) and one SAE (febrile convulsion) were considered as potentially related to
MMR-RIT and M-M-R II, respectively. This study showed that antibodies against measles, mumps and
rubella persisted for up to 2 y post-vaccination with either MMR vaccine in children aged 12–15 months,
and that both vaccines were well-tolerated during the follow-up period.
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Introduction
Measles, mumps and rubella (MMR) combined vaccine, which
has been available in the United States of America (USA) since
1971,1 has greatly reduced the incidence of these diseases.2 Nevertheless, attaining high vaccine coverage and maintaining
these levels are essential in the prevention and elimination of
these childhood infectious illnesses.3,4
Although the vaccine coverage for at least one dose of MMR
vaccine was 91.5% in 2014, one in every 12 children in the USA
did not receive their ﬁrst dose of vaccine on time, causing high
measles susceptibility in some locations.5 Reasons for low coverage of measles vaccine in certain areas could be due to vaccine
hesitancy and lack of access to care,5 or intentional non-vaccination due to personal beliefs.6
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Measles outbreaks occur predominantly in unvaccinated individuals, and are facilitated by low coverage as well as the high
transmissibility of the measles virus.7,8 As a result of sub-optimal
vaccine uptake, the USA has experienced several recent measles
outbreaks.8 In 2014 and 2015, 667 and 189 cases of measles
were reported to the Center for Disease Control (CDC), respectively, and in 2016, a preliminary count of 70 measles cases were
reported in the USA.6,8,9 The largest outbreak in 2015 originated
at an amusement park in California, and largely affected unvaccinated children.6 In 2014, a single large outbreak affecting 383
cases occurred primarily among unvaccinated Amish communities in Ohio. Many cases in 2014 were associated with people
migrating from the Philippines, where there had been a large
outbreak of measles.6,10,11
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MMR vaccination is recommended in over 100 countries,
including the European Union, North America and Australasia.12 In the USA, the Advisory Committee on Immunization
Practices recommends 2 doses of MMR vaccine for children,
with the ﬁrst dose administered at 12¡15 months of age followed by a second dose usually given before school entry in
children aged 4 to 6 y (the second dose can be administered
any time, with a minimum of 28 d between the doses).3 Currently there is only one MMR vaccine licensed in the USA (MM-R II; Merck, USA), and any interruption to this single supply
line could be a public health risk.3 Another MMR vaccine, PriorixTM (MMR-RIT [RIT strain 4385]; GSK, Belgium), is
licensed in over 100 countries13 and has been shown to be
immunogenic and well-tolerated in trials conducted in the
USA.13-15 Furthermore, as the MMR-RIT vaccine, like the current formulation of the M-M-R II vaccine, is manufactured
without Human Serum Albumin (HSA) in accordance with the
European Medicines Agency (EMA) guidelines, the theoretical
risk of microbial contamination is reduced compared with previous formulations of the M-M-R II vaccine.16,17
We described previously the short-term antibody responses to
ﬁrst doses of MMR-RIT and M-M-R II administered to healthy
US children between 12–15 months of age;13 in this article, we
report the antibody persistence at one and 2 y post-vaccination.

Results
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group) or low (103.7 CCID50; MMR-RIT-3 group), or the MM-R II vaccine (M-M-R II group). Of these, 880 children completed the 2-year persistence phase (Fig. 1). The according-toprotocol (ATP) cohort for the persistence phase included 752
children, who had no exclusion criteria for the study, had not
received a vaccine forbidden in the protocol, complied with
blood sampling schedules, and for whom immunogenicity end
point measures were available for pre-vaccination, Day 42 and
Year 2 post-vaccination.
The ATP persistence cohort had a mean age at primary vaccination of 12.3 (standard deviation: § 0.6) months; 78.1% of
children were White/Caucasian and 51.6% were male. The
demographic characteristics were similar among the 4 treatment groups (Table 1).
In this study, a total of 104 (8.5%) children were revaccinated
(MMR-RIT-1 [24/304; 7.9%]; MMR-RIT-2 [24/304; 7.9%];
MMR-RIT-3 [34/304; 11.2%]; M-M-R II [22/308; 7.1%]) after
the visit at Day 42 (86 children) or Year 1 (18 children). Among
the 104 revaccinated children, 84 received the additional MMRcontaining vaccine dose (either M-M-R II or ProQuadÒ [Merck,
USA]) after being identiﬁed as sub-optimal responders for at
least one antigen at Day 42, and 20 were revaccinated for other
reasons; their serology results for timepoints after revaccination
were excluded from the analysis. There were an additional 19
sub-optimal responders identiﬁed at Day 42 who were not revaccinated and therefore were included in the analyses.

Demographic data
In the primary phase of the study, 1220 children received a single dose of either one of 3 MMR-RIT lots, each containing different RIT 4385 mumps strain titers: high (104.8 CCID50;
MMR-RIT-1 group), medium (104.1 CCID50; MMR-RIT-2

Immunogenicity
Measles
Seropositivity rates for anti-measles antibodies were 98.3–100%
across the 3 MMR-RIT groups and 99.4% in the M-M-R II

Figure 1. Disposition of participants in the total vaccinated cohort (persistence phase). ATP, according-to-protocol; MMR: Measles Mumps Rubella vaccine. For children
revaccinated at any point in the study, data were censored from analysis for timepoints after revaccination.
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Table 1. Demographic characteristics (ATP cohort for persistence).
Characteristics

Categories

Age at dose 1
(months)

Mean
SD

Gender

Female
Male
African heritage
American Indian or Alaskan native
South East Asian heritage
Paciﬁc islander
North African heritage
European heritage
Other

Race

MMR-RIT-1N D 189

MMR-RIT-2 N D 181

MMR-RIT-3 N D 196

M-M-R IIN D 186

12.3
0.67

12.3
0.66

12.2
0.55

12.3
0.67

n
98
91
14
0
1
2
2
150
20

%
51.9
48.1
7.4
0.0
0.5
1.1
1.1
79.4
10.6

n
87
94
15
0
1
0
0
140
25

%
48.1
51.9
8.3
0.0
0.6
0.0
0.0
77.3
13.8

n
100
96
16
0
0
1
1
154
24

%
51.0
49.0
8.2
0.0
0.0
0.5
0.5
78.6
12.2

n
79
107
18
1
0
2
3
143
19

%
42.5
57.5
9.7
0.5
0.0
1.1
1.6
76.9
10.2

MMR-RIT-1: lot 1 of MMR
MMR-RIT-2: lot 2 of MMR
MMR-RIT-3: lot 3 of MMR
M-M-R II: Merck’s MMR vaccine
N D total number of children
SD: Standard deviation
n/% D number / percentage of children in a given category

group at Year 1, and 99.4–100% across the 3 MMR-RIT groups
and 100% in the M-M-R II group at Year 2.
Anti-measles antibody geometric mean concentrations
(GMCs) persisted through Years 1 and 2, and remained at least
as high as those recorded at Day 42; the ranges were
3230.2¡4022.1 mIU/mL across the 4 groups (Table 2). These
antibody responses against the measles virus were at least 16fold higher than the seroresponse threshold at Years 1 and 2.
Among the 10 children who had sub-optimal measles responses
at Day 42 and were revaccinated during the 2-year period following vaccination, 8 had post-revaccination titers above the
threshold for measles and 2 did not have post-revaccination
blood samples.
Mumps
Using the PPD ELISA, seropositivity rates were 90.1–90.8%
across the 3 MMR-RIT groups and 95.9% for the M-M-R II
group at Year 1, and 94.1–96.5% across the 3 MMR-RIT groups
and 95.7% for the M-M-R II group at Year 2. The corresponding GMCs at Years 1 and 2 across the 4 groups were at least 4fold higher than the seroresponse threshold (Table 2).
Using the unenhanced-PRN assay, seropositivity rates
were 87.5–89.4% across the 3 MMR-RIT groups and 88.6%
in the M-M-R II group at Year 1, and 91.7–96.8% across
the 3 MMR-RIT groups and 94.7% in the M-M-R II group
at Year 2. The corresponding geometric mean titers
(GMTs) across the 4 groups at Years 1 and 2 were also
observed to be at least 8-fold higher than the seroresponse
threshold (Table 2).
Sixty-six of 72 (91.7%) children who were revaccinated during the 2-year period following vaccination due to sub-optimal
response for mumps at Day 42 (based on the enhanced-plaque
reduction neutralization [PRN] assay) were above the thresholds for mumps PRN (using unenhanced-PRN assay) or puriﬁed protein derivative (PPD) enzyme-linked immunosorbent
assay (ELISA) following revaccination, 4/72 (5.6%) had no
post-revaccination blood samples, and 2/72 (2.8%) were below
the seroresponse threshold of the mumps PPD ELISA following
revaccination.

Rubella
The seroresponse for rubella was similar in all 4 vaccine
groups, ranging from 98.9–99.5% for the 3 MMR-RIT
groups and reaching 100% for the M-M-R II group at Year
1, while at Year 2, all children were seropositive in the 4
groups (Table 2). The corresponding GMCs were higher at
Year 1 (range: 134.8¡165.7 IU/mL) than at pre-vaccination,
but declined at Year 2 (range: 78.0¡93.1 IU/mL) across the
4 groups. These antibody responses against rubella were at
least 8-fold higher than the seroresponse threshold at Years
1 and 2 (Table 2). Among the 8 children who had sub-optimal rubella responses at Day 42 and were revaccinated during the 2-year period following vaccination, 7 were above
the thresholds for rubella following revaccination, and one
did not have post-revaccination blood samples.
Safety
During the extended safety follow-up phase (up to
6 months), 32 serious adverse events (SAEs) were reported
in 22 children: MMR-RIT-1 (n D 1), MMR-RIT-2 (n D 6),
MMR-RIT-3 (n D 7), M-M-R II (n D 8). Three SAEs were
considered by the investigators as potentially related to the
study vaccine: one case of inguinal adenitis at Day 68 in
the MMR-RIT-1 group, which resolved within 14 days; one
case of grade 2 idiopathic thrombocytopenic purpura with
onset at Day 20 in the MMR-RIT-2 group, which resolved
within 212 days; and one case of grade 2 febrile convulsion
on Day 0 in the M-M-R II group, which resolved within
one day. All SAEs resolved and no fatal SAEs were reported
up to 6 months. New onset chronic illness (NOCI) were
reported in 13 children: MMR-RIT-1 (n D 5), MMR-RIT-2
(n D 2), MMR-RIT-3 (n D 4), M-M-R II (n D 2).
During the persistence phase (up to 2 y post-vaccination), one child developed nephroblastoma after vaccination
with M-M-R II and was withdrawn from the study. This
event was not causally related to vaccination as deemed by
the investigator. No children experienced SAEs related to
study participation, and no deaths occurred during the
study.
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Table 2. Percentage of children with anti-measles, mumps and rubella antibodies
in initially seronegative children (ATP cohort for persistence).
Group
MMR-RIT-1
MMR-RIT-2
MMR-RIT-3
M-M-R II

MMR-RIT-1
MMR-RIT-2
MMR-RIT-3
M-M-R II

MMR-RIT-1
MMR-RIT-2
MMR-RIT-3
M-M-R II

MMR-RIT-1
MMR-RIT-2
MMR-RIT-3
M-M-R II

Timing

N

n

% (95% CI)

GMC (95% CI)

D42
Y1
Y2
D42
Y1
Y2
D42
Y1
Y2
D42
Y1
Y2

Anti-measles antibody 200 mIU/mL
182 181 99.5 (97.0¡100) 2779.3 (2509.9¡3077.7)
179 178 99.4 (96.9¡100) 3230.2 (2820.4¡3699.7)
171 171 100 (97.9¡100) 3361.1 (2922.3¡3865.6)
172 169 98.3 (95.0¡99.6) 3010.1 (2669.0¡3394.7)
175 172 98.3 (95.1¡99.6) 3766.9 (3245.6¡4372.0)
159 159 100 (97.7¡100) 3963.8 (3479.3¡4515.7)
186 184 98.9 (96.2¡99.9) 2703.0 (2446.6¡2986.3)
191 191 100 (98.1¡100) 3521.5 (3094.6¡4007.3)
169 168 99.4 (96.7¡100) 3360.3 (2923.3¡3862.7)
178 177 99.4 (96.9¡100) 2749.6 (2469.9¡3061.0)
178 177 99.4 (96.9¡100) 3930.4 (3423.3¡4512.7)
166 166 100 (97.8¡100) 4022.1 (3507.7¡4611.9)

D42
Y1
Y2
D42
Y1
Y2
D42
Y1
Y2
D42
Y1
Y2

Anti-mumps (PPD ELISA) 10 ELU/mL
159 152 95.6 (91.1¡98.2)
56.8 (48.7¡66.3)
141 127 90.1 (83.9¡94.5)
47.0 (37.9¡58.2)
136 128 94.1 (88.7¡97.4)
47.8 (40.2¡56.9)
153 142 92.8 (87.5¡96.4)
43.4 (37.3¡50.4)
142 129 90.8 (84.9¡95.0)
40.1 (33.4¡48.0)
130 125 96.2 (91.3¡98.7)
50.2 (42.1¡59.9)
46.1 (39.5¡53.8)
169 153 90.5 (85.1¡94.5)
154 139 90.3 (84.4¡94.4)
43.9 (36.5¡52.9)
141 136 96.5 (91.9¡98.8)
54.0 (46.1¡63.3)
158 148 93.7 (88.7¡96.9)
55.3 (47.9¡63.8)
146 140 95.9 (91.3¡98.5)
57.4 (49.1¡67.0)
140 134 95.7 (90.9¡98.4)
59.2 (50.1¡70.0)

Anti-mumps (unenhanced PRN assay)  4 ED50
D42
71
53 74.6 (62.9¡84.2)
11.8 (8.4¡16.5)
Y1
161 142 88.2 (82.2¡92.7)
33.1 (24.9¡44.2)
Y2
157 144 91.7 (86.3¡95.5)
43.4 (33.4¡56.3)
D42
69
55 79.7 (68.3¡88.4)
17.3 (11.8¡25.4)
Y1
170 152 89.4 (83.8¡93.6)
40.2 (31.0¡52.1)
Y2
144 134 93.1 (87.6¡96.6)
48.9 (37.7¡63.5)
D42
73
61 83.6 (73.0¡91.2)
16.0 (11.4¡22.4)
Y1
184 161 87.5 (81.8¡91.9)
42.7 (32.9¡55.4)
Y2
157 152 96.8 (92.7¡99.0)
57.4 (45.7¡72.2)
D42
82
59 72.0 (60.9¡81.3)
14.3 (10.3¡19.9)
Y1
167 148 88.6 (82.8¡93.0)
46.4 (35.7¡60.3)
Y2
152 144 94.7 (89.9¡97.7)
60.7 (47.6¡77.5)
D42
Y1
Y2
D42
Y1
Y2
D42
Y1
Y2
D42
Y1
Y2

Anti-rubella antibody 10 IU/mL
182 180 98.9 (96.1¡99.9)
74.3 (66.4¡83.1)
179 177 98.9 (96.0¡99.9)
136.4 (121.4¡153.3)
171 171 100 (97.9¡100)
78.0 (69.7¡87.2)
170 167 98.2 (94.9¡99.6)
74.4 (65.8¡84.0)
174 173 99.4 (96.8¡100)
134.8 (121.4¡149.8)
158 158 100 (97.7¡100)
79.5 (71.7¡88.2)
185 182 98.4 (95.3¡99.7)
67.8 (61.0¡75.5)
190 189 99.5 (97.1¡100)
135.6 (122.0¡150.7)
168 168 100 (97.8¡100)
81.7 (73.8¡90.4)
178 178 100 (97.9¡100)
89.6 (80.3¡100.0)
178 178 100 (97.9¡100)
165.7 (149.4¡183.9)
166 166 100 (97.8¡100)
93.1 (83.6¡103.6)

MMR-RIT-1: lot 1 of MMR
MMR-RIT-2: lot 2 of MMR
MMR-RIT-3: lot 3 of MMR
M-M-R II: Merck’s MMR vaccine
D42D Post-vaccination blood sample at Day 42
Y1D Antibody persistence blood sample at Year 1
Y2D Antibody persistence blood sample at Year 2
N D number of subjects with available results; n/% D number/percentage of children with concentration above the speciﬁed value; 95% CI D 95% conﬁdence
interval
GMCD geometric mean antibody concentration calculated on all children

Enhanced PRN assay was used in the ﬁrst year and unenhanced PRN assay was
used in the second year
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Discussion
Our results indicate that protective immune responses to measles, mumps, and rubella observed immediately after administration of a single dose of any of the 3 MMR-RIT lots
(containing different mumps virus titers) or M-M-R II persisted for at least 2 y post-vaccination. The immune responses
observed in this persistence study were at least as high as the
primary responses observed at 42 d post-vaccination, with antibody GMCs/GMTs at Years 1 and 2 remaining at least 4-fold
higher than the seroresponse thresholds. These persistence data
indicate that protection against the 3 viruses is likely to be
maintained between the ﬁrst dose given at 12–15 months of
age and the second dose administered at 4¡6 y of age.
Our observations with respect to the persistence of measles
and rubella antibodies are consistent with previous ﬁndings
with the MMR-RIT vaccine.18-20 Dine et al. showed that antibodies to measles persist for up to 26–33 y after a 2-dose vaccination schedule (dose 1 administered predominantly during
the ﬁrst year of life and revaccination 1¡7 y thereafter).21 In
the present study, we observed that mumps neutralizing antibody titers and corresponding antibody GMTs were either
maintained or steadily rose over time, which has also been
noted previously.22,23 As in our study, these previous publications reported low neutralization titers immediately post-vaccination that then rose in the long-term follow-up period,
suggesting that the development of neutralizing antibody titers
is rather slow after vaccination. In contrast, ELISA proved to be
more sensitive in detecting mumps antibodies soon after vaccination, with only a small increase in the late post-vaccination
period.22,23 Although rubella seroconversion was not lost over
time, we observed an increase in rubella antibodies at Year 1
with a subsequent decline at Year 2 post-primary vaccination.
Nevertheless, the Year 2 antibody GMCs were comparable to
those observed at Day 42 post-vaccination, suggesting that
immunity persists for at least 2 y. The lower response observed
at Day 42 could be because the incubation period for the wild
type rubella virus replication is up to 21 days, suggesting that
the development of the full antibody response could take longer
than 42 d.24
A secondary, yet noteworthy aspect of our study is the use of
2 different assays to analyze the mumps titers and seroresponse
over 2 y. Although there is no proven correlate of protection
for mumps, functional assays, such as the PRN assay, are probably a better estimate compared with ELISA because neutralization is a functional aspect of antibodies, whereas ELISA
measures total antibodies whether functional or not. In this
study, the unenhanced PRN assay yielded seroresponse rates
>70% at Day 42 post-vaccination, which is consistent with
effectiveness studies following single dose vaccination.25 We
saw a more pronounced rise in antibody titers over time with
PRN assay than with ELISA, likely because antibody levels as
measured by PRN continued to increase after vaccination.
Recently, Latner et al. measured mumps antibody levels using
both PRN assay and ELISA speciﬁc for the mumps nucleoprotein and hemagglutinin.26 They proposed that the differences
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in the response to the individual mumps proteins could partially explain the lack of correlation between the different serological tests.26 The data further indicated that some individuals
who were seropositive by ELISA had low levels of neutralizing
antibodies, suggesting that previous estimates of immunity
based on whole virus ELISA may be overstated.26
We studied the persistence of antibodies against measles,
mumps and rubella in the context of an investigational MMR
vaccine (without HSA), co-administered with existing standard
of care vaccines; this is a major strength of this study. The persistence data reﬂect antibody GMT/GMC values at 12 and
24 months after the ﬁrst dose of MMR vaccine, which were
measured in children aged 2 and 3 y, before the second dose
administration, which is usually scheduled at 4 to 6 y of age.
The functional antibody assays used in this study to evaluate
the persistence of the immune response to mumps are important, as there is currently no proven correlate of protection. We
also evaluated persistence in a non-endemic setting, where children would have limited ongoing exposure to such viruses, suggesting that the observed antibody responses represent true
vaccine antibody persistence.
It is important to note that since this antibody persistence
analysis was a secondary analysis of the overall study, the results
are only descriptive. Another limitation of this study was that a
small group of children (8.5%) were revaccinated, and their data
were censored from this analysis for timepoints after revaccination. As these children received a second dose of MMR during
the 2-year period following vaccination, inclusion of these children would have overestimated antibody persistence following
one dose of MMR vaccine. The requirement to switch the
mumps PRN assay during the study was also a limitation; however, since the old PRN assay used in the ﬁrst year is known to
overestimate titers and likely overestimate protection,27 the use
of the new PRN assay can be perceived as a strength.
In conclusion, antibodies against measles, mumps and
rubella viruses persisted for up to 2 y after primary vaccination
at 12–15 months of age with MMR-RIT and M-M-R II vaccines
in healthy children. Serological results were comparable for the
USA licensed comparator and the investigational MMR-RIT
vaccine, and both vaccines were well tolerated during the 2-y
post-vaccination follow-up.

Methods
Study design
The initial phase II, randomized, observer-blind study was conducted between June 2009 and July 2010 at 48 centers in the
USA and 3 centers in Puerto Rico (NCT00861744).13 In this
study, we continued to follow children for 2 y post-primary
vaccination. In the primary phase,13 12¡15 month-old children
who had not been previously immunized against (and had no
previous history of) measles, mumps, rubella, varicella and hepatitis A, and had received 3 doses of 7-valent pneumococcal
conjugate vaccine (PCV7) within the ﬁrst year of life (third
dose administered  30 d before enrollment) were enrolled.
Exclusion criteria are listed in the previous publication.13
In the primary vaccination study, children were randomized
into 4 treatment groups and received single doses of either one

of 3 MMR-RIT lots (MMR-RIT-1, MMR-RIT-2 or MMR-RIT3) or M-M-R II.3 Children also received concomitant single
doses of hepatitis A vaccine (HAV), varicella vaccine (VAR),
and the fourth dose of PCV7.
This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and
each local site was approved by a national, regional, or investigational center institutional review board or independent ethics
committee. Written informed consent was obtained from
parents/guardians before enrollment.

Immunogenicity assessment
Blood samples were collected at Year 1 and Year 2 post-primary vaccination. Sera were stored at ¡20 C until assayed in a
blinded manner at a central laboratory (GSK, Rixensart,
Belgium).
Immunoglobulin (IgG) antibodies to measles and rubella
were measured using a commercial ELISA, EnzygnostTM (Dade
Behring, Marburg GmbH, Germany). The test was performed
and interpreted as directed by the manufacturer. The complement and IgG enhanced-PRN assay used to assess mumps seropositivity in the ﬁrst year was replaced with a PRN assay
without complement and without anti-immunoglobulin
enhancement (unenhanced-PRN; using the wild-type virus,
MU-90)27 to assess the production of neutralizing antibodies.
In addition, IgG antibodies to the mumps virus were measured
using a quantitative PPD-ELISA (Merck, USA). The replacement of the enhanced-PRN assay with the 2 new assays for the
assessment of mumps seropositivity was performed in accordance with the guidance from the Center for Biological Evaluation and Research.
Pre-vaccination, samples were deﬁned as seronegative to the
different viral antigens if assay results were below the following
cut-off values: <150 mIU/mL for measles; <24 ED50
(enhanced-PRN assay) and <5 EU/mL (ELISA) for mumps;
and <4 IU/mL for rubella. The seronegativity cut-offs evaluated in this study had been determined empirically as part of
assay validation and were accepted by the USA Food and Drug
Administration (FDA).
Testing to evaluate for sub-optimal response was performed
at Day 42. In the case of mumps, this testing was based on the
enhanced-PRN assay.13 A sub-optimal response was deﬁned as
antibody concentrations/titers of measles <200 mIU/mL,
mumps <51 ED50 (enhanced-PRN assay) and rubella <10 IU/
mL. Any child with a sub-optimal response at Day 42 post-vaccination was given the option of being revaccinated. For analyses of antibody responses, data from children who were
revaccinated were removed from analysis for timepoints after
revaccination.
Post-vaccination seroresponses for MMR vaccine viral antigens in initially seronegative children were deﬁned as antibody
concentrations/titers of:  200 mIU/mL for measles;  10 EU/
mL (PPD ELISA),  51 ED50 (enhanced-PRN assay), or  4
ED50 (unenhanced-PRN assay) for mumps; and  10 IU/mL
for rubella. The seroresponse thresholds evaluated in this study
were accepted by the FDA as thresholds deﬁning active immunization offering clinical beneﬁt.
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Safety assessment
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An extended safety follow-up assessed SAEs for up to
6 months post-primary vaccination. During this period, we
also recorded any new onset chronic illnesses including
autoimmune disorders, asthma, type I diabetes, allergies,
and conditions prompting emergency department visits.
SAEs related to study participation prompting study withdrawal and/or leading to death were recorded for up to 2 y
post-vaccination.
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